COMMUNIQUÉS West-GlobeNewswire

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
04/11/2025
Platinum sponsorship of NF Caregivers Symposium reinforces commitment to NF1 community MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage [...]
Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025
04/11/2025
Oslo, 4 November 2025: Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement and retail offering. The Company's board of [...]
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights
04/11/2025
Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved target randomization [...]
Prelude Therapeutics Announces Strategic Business Update
04/11/2025
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement [...]
Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan
04/11/2025
Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% on an adjusted pro [...]
Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference
04/11/2025
MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the [...]
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
04/11/2025
CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences
04/11/2025
Average Percent Area Reduction of 97% in 4 weeks in diabetic wounds 100% diabetic wound closure in ≤ 12 weeks Preclinical sustained antibiofilm activity for a minimum of 7 days WINNIPEG, Manitoba, Nov. 04, 2025 (GLOBE [...]
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
04/11/2025
NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the [...]
Repligen Corporation to Present at Upcoming November Conferences
04/11/2025
WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending five upcoming [...]
Bioventus Reports Third Quarter Financial Results
04/11/2025
Q3 reported revenue of $138.7 million was comparable to last year and organic* revenue advanced 8% Third quarter GAAP earnings of $0.05 per diluted share increased compared to the prior-year period loss of $0.08 per [...]
BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models
04/11/2025
SITC poster to be presented on Friday, November 7, 2025, emphasizes robust anti-cancer activity of next generation Bria-OTS+ platform Lead candidates Bria-BRES+™ (breast cancer) and Bria-PROS+™ (prostate cancer) [...]
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
04/11/2025
WAYNE, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients [...]
BridgeBio to Participate in November Investor Conferences
04/11/2025
PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that [...]
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
04/11/2025
PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Erasca to Present at Upcoming Conferences in November
04/11/2025
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
Certara Automates Scientific Workflows with Phoenix® Cloud
04/11/2025
New cloud capabilities cut time to create Tables, Figures, and Listings by 50% RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today [...]
Jasper Therapeutics to Present at Upcoming Investor Conferences
04/11/2025
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Exagen Inc. Reports Strong Q3 2025 Results
04/11/2025
CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent [...]

Pages